NCT05737576View on ClinicalTrials.gov

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

October 26, 2023

Study Completion Date

December 8, 2023

Conditions
Diabetes
Interventions
DRUG

HR011408 injection; NovoRapid®

HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.

DRUG

NovoRapid®；HR011408 injection

NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.

DRUG

HR011408 injection; NovoRapid®

HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.

DRUG

NovoRapid®；HR011408 injection

NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.

DRUG

HR011408 injection; NovoRapid®

HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.

DRUG

HR011408 injection; NovoRapid®

NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.

Trial Locations (1)

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY